11
Participants
Start Date
October 23, 2019
Primary Completion Date
September 25, 2020
Study Completion Date
September 25, 2020
Pimavanserin
Pimavanserin 34 mg (provided as 2×17 mg encapsulated tablets) administered orally as a single dose once daily
Placebo
Placebo (provided as 2 × placebo encapsulated tablets) administered orally as a single dose once daily
Quetiapine
Quetiapine 25 mg (provided as 1×25 mg quetiapine encapsulated tablet and 1 × placebo encapsulated tablet), OR 50 mg (provided as 2×25 mg quetiapine encapsulated tablets), OR 100 mg (provided as 2×50 mg quetiapine encapsulated tablets) administered orally as a single dose once daily
M3 Wake Research, Inc., Raleigh
Prisma Health-Upstate, Greenville
Galiz Research, Hialeah
Meridian Clinical Research, Savannah
Charter Research, LLC, Lady Lake
Charter Research, LLC, Winter Park
Premier Clinical Research Institute, Inc., Miami
Infinity Clinical Research, LLC, Sunrise
Dayton Center for Neurological Disorders, Centerville
SRI International, Plymouth
University of lowa Hospital and Clinics, Iowa City
Movement Disorders Center of Arizona, Scottsdale
Tucson Neuroscience Research, Tucson
Sutter Institute for Medical Research, Sacramento
Hawaii Pacific Neuroscience, LLC., Honolulu
Bio Behavioral Health, Toms River
Lead Sponsor
ACADIA Pharmaceuticals Inc.
INDUSTRY